GLP-1 and GIP appear together so often that they read as one thing with two names. They are two hormones, from two genes, released by two kinds of cell, acting on two receptors. The differences are what make a compound that engages both worth studying at all.

What they share

Both are incretins: gut hormones released when nutrients arrive, contributing to the insulin response that follows. Both act through receptors in the same structural family, the one that also contains the glucagon and secretin receptors. (Reference: Mayo et al., 2003) And both are cut by the same enzyme at the same position, which is covered below.

Different origins

Each hormone comes from its own precursor protein, encoded by its own gene, and each is released by a different population of enteroendocrine cells. The cells that release GIP are concentrated in the upper small intestine. The cells that release GLP-1 are more common further along. (Reference: Baggio & Drucker, 2007)

That geography has a practical consequence for reading the literature. An experiment that changes where nutrients are absorbed changes the balance between the two signals, so two studies can describe the same system and see different mixtures.

Different receptors, and why that is the whole point

The GIP receptor and the GLP-1 receptor are separate proteins with separate distributions across tissues. Activating one does not activate the other. Both feed into the regulation of glucose, and both belong to the same receptor class, but they are not two doors into the same room.

This is what makes a specific laboratory question possible: what changes when a single molecule engages both at once, compared with engaging either alone? A question like that only has meaning because the receptors are distinct.

Tissue distribution is the second half of that answer. A receptor only matters where it is expressed, so two receptors that both regulate glucose can still reach different tissues and produce different patterns of activity from the same starting signal.

Both are clipped by the same enzyme

Dipeptidyl peptidase-4 removes the first two residues from the end of both hormones, and the clipped product no longer activates the receptor the way the intact form does. (Reference: Mentlein, 1999)

The shared vulnerability explains a shared design pattern. Synthetic compounds aimed at either receptor tend to carry a substitution near that cleavage site, and many also carry a fatty acid chain that lets them associate with serum albumin and be cleared more slowly. (Reference: Hijazi, 2021) Both modifications are visible in the molecule, and both change its mass and its behaviour on a column.

How the receptors hold their ligand

Receptors in this family are built in two parts: a large domain outside the cell and the usual seven membrane-spanning helices. The peptide binds across both. One end of the hormone is gripped by the extracellular domain, and the other end reaches into the core of the transmembrane bundle, where it does the work of switching the receptor on. (Reference: Mayo et al., 2003)

The arrangement explains two things at once. It is why both hormones are long peptides instead of small molecules, since a short ligand cannot reach both sites. And it is why a chemist has room to work: a molecule that touches the receptor along an extended interface tolerates substitution at positions that are not doing the binding, which is where the modifications in synthetic compounds go.

Names and numbers

Both hormones appear in the literature with numeric ranges attached, because each is a fragment cut from a longer precursor and more than one fragment exists. Some circulating forms end in an amide instead of a free acid. Those details are not bookkeeping: they change the formula and therefore the mass, so a specification that quotes a range and an ending is quoting something an identity measurement can confirm or contradict.

Which is better studied

GLP-1 has the larger literature by a wide margin, and for years the GIP arm attracted less attention. That imbalance is part of why dual engagement became an active question: the less-studied receptor was the open variable.

Anyone reading older work should keep the dates in view. Conclusions drawn when one arm was barely characterised are not wrong, but they were drawn with less of the picture available.

Counting receptors is not measuring activity

Compounds in this space are often described by how many receptors they engage: one for a GLP-1 agonist, two for a dual agonist, three for a triple agonist that adds the glucagon receptor. The count is easy to state and easy to over-read. It describes how many targets a molecule was designed to reach, and says nothing about how strongly it reaches each one.

A compound can engage two receptors unevenly, and it can favour one downstream route over another at the same receptor. One dual agonist has been characterised in exactly those terms. (Reference: Willard et al., 2020) The vocabulary for this sits in our note on agonists and antagonists, and the short version is that "dual" is a label, not a measurement.

What the comparison does not settle

Knowing how the two hormones differ tells you what a compound is designed to do. It tells you nothing about the material in a vial. Whether a given batch contains the intended molecule, and how much of it is that molecule, comes from a purity measurement by HPLC and an identity measurement by mass spectrometry, both printed on a certificate under the batch number you can look up.

Research use only

This article is background biology for laboratory context. All products sold by Codex Research are strictly for research and development, are not for human or animal consumption, and are not intended to diagnose, treat, cure, or prevent any disease.

These compounds in the catalog

Frequently asked questions

Are GLP-1 and GIP the same thing?

No. They are two hormones from two genes, released by different populations of gut cells, acting through two separate receptors. They share a receptor family and a common route of degradation.

Where is each hormone released?

The cells that release GIP are concentrated in the upper small intestine, and the cells that release GLP-1 are more common further along. An experiment that changes where nutrients are absorbed changes the balance between the two signals.

Do the two receptors overlap?

They are separate proteins with separate distributions across tissues, and activating one does not activate the other. Both belong to the same receptor family and both feed into glucose regulation.

Why are both hormones short-lived?

Dipeptidyl peptidase-4 removes the first two residues from each of them, and the clipped product no longer activates the receptor as the intact form does. That shared vulnerability explains a shared design pattern in synthetic compounds.

Which of the two is better studied?

GLP-1, by a wide margin. The GIP arm attracted less attention for years, which is part of why engaging both at once became an active research question: the less-studied receptor was the open variable.

Does a dual agonist affect both receptors equally?

Not necessarily. One dual agonist has been characterised as unbalanced across its two targets and as favouring some downstream routes over others. The number of receptors in a description is a label, not a measurement.

References

Related articles